Advertisement

pp 1-17 | Cite as

Strategies for Multi-Target Directed Ligands: Application in Alzheimer’s Disease (AD) Therapeutics

Protocol
Part of the Methods in Pharmacology and Toxicology book series

Abstract

Design of multi-target directed ligand (MTDL) is believed to be a novel and improved approach for diseases that elucidate a multifactorial nature. Alzheimer’s disease (AD) is related to increased levels of the amyloid β peptide (Aβ), the hyperphosphorylated tau protein, free radicals, oxidized proteins and lipids, metal ion dysregulation and many more. For the multifactorial aetiology of AD and the fact that till date there is no effective treatment besides drugs alleviating associated symptoms, molecules designed to hit simultaneously different key targets of the complex pathological network emerges as a more realistic alternative. In this context, the present chapter puts forward a note of several strategies adopted for the development of MTDLs for the disease followed by a case study leading to in vitro validation.

Keywords

Anti-amyloidogenic Antioxidant Aβ BACE1 Inhibitor MTDL QSAR Virtual screening 

References

  1. 1.
    Rutherford GW, Sangani PR, Kennedy GE (2003) Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst Rev (4):CD002037Google Scholar
  2. 2.
    Chung KF, Adcock IM (2004) Combination therapy of long-acting b2-adrenoceptor agonists and corticosteroids for asthma. Treat Respir Med 3(5):279–289Google Scholar
  3. 3.
    Frishman WH, Zuckerman AL (2004) Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev Cardiovasc Ther 2(5):675–681Google Scholar
  4. 4.
    Zerkak D, Dougados M (2004) Benefit/risk of combination therapies. Clin Exp Rheumatol 22(5 Suppl 35):S71–S76Google Scholar
  5. 5.
    Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4(1):71–78Google Scholar
  6. 6.
    Smid P, Coolen HK, Keizer HG et al (2005) Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[w-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition. J Med Chem 48(22):6855–6869Google Scholar
  7. 7.
    Holmes HM, Sachs GA, Shega JW et al (2008) Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc 56(7):1306–1311Google Scholar
  8. 8.
    Van der Schyf CJ, Youdim MB (2009) Multifunctional drugs as neurotherapeutics. Neurotherapeutics 6(1):1–3Google Scholar
  9. 9.
    Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48(21):6523–6543Google Scholar
  10. 10.
    Morphy R, Rankovic Z (2009) Designing multiple ligands – medicinal chemistry strategies and challenges. Curr Pharm Des 15(6):587–600Google Scholar
  11. 11.
    Stahl SM (2009) Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr 14(2):71–73Google Scholar
  12. 12.
    Youdim MB, Van der Schyf CJ (2007) Magic bullets or novel multimodal drugs with various targets for Parkinson’s disease? Nat Rev Drug Discov 6(6):iii–iviGoogle Scholar
  13. 13.
    Bolognesi ML, Matera R, Minarini A et al (2009) Alzheimer’s disease: new approaches to drug discovery. Curr Opin Chem Biol 13(3):303–308Google Scholar
  14. 14.
    Bolognesi ML, Rosini M, Andrisano V (2009) MTDL design strategy in the context of Alzheimer’s disease: from lipocrine to memoquin and beyond. Curr Pharm Des 15(6):601–613Google Scholar
  15. 15.
    Pruss RM (2010) Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol Disord Drug Targets 9(6):693–700Google Scholar
  16. 16.
    Levy OA, Malagelada C, Greene LA (2009) Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis 14(4):478–500Google Scholar
  17. 17.
    Bar-Am O, Amit T, Weinreb O et al (2010) Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-b protein precursor: involvement of MAPK and PKC activation. J Alzheimers Dis 21(2):361–371Google Scholar
  18. 18.
    Van der Schyf CJ, Geldenhuys WJ, Youdim MB (2006) Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J Neurochem 99(4):1033–1048Google Scholar
  19. 19.
    Chertkow Y, Weinreb O, Youdim MB et al (2009) Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. J Neural Transm 116(11):1529–1541Google Scholar
  20. 20.
    Huang W, Tang L, Shi Y, Huang S, Xu L, Sheng R, Wu P, Li J, Zhou N, Hu Y (2011) Searching for the multi-target-directed ligands against Alzheimer’s disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities. Bioorg Med Chem 19(23):7158–7167Google Scholar
  21. 21.
    Fang J, Li Y, Liu R, Pang X, Li C, Yang R, He Y, Lian W, Liu AL, Du GH (2015) Discovery of multi target-directed ligands against Alzheimer’s disease through systematic prediction of chemical-protein interactions. J Chem Inf Model 55(1):149–164Google Scholar
  22. 22.
    Rosini M, Simoni E, Minarini A, Melchiorre C (2014) Multi-target design strategies in the context of Alzheimer’s disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. Neurochem Res 39(10):1914–1923Google Scholar
  23. 23.
    Luo Z, Sheng J, Sun Y, Lu C, Yan J, Liu A, Luo HB, Huang L (2013) Synthesis and evaluation of multi-target-directed ligands against Alzheimer’s disease based on the fusion of donepezil and ebselen. J Med Chem 56(22):9089–9099Google Scholar
  24. 24.
    Chakraborty S, Bandyopadhyay J, Chakraborty S, Basu S (2016) Multi-target screening mines hesperidin as a multi-potent inhibitor: implications in Alzheimer’s disease therapeutics. Eur J Med Chem 121:810–822Google Scholar
  25. 25.
    Hyperchem (2002) Hypercube, Inc., USAGoogle Scholar
  26. 26.
    Chakraborty S, Basu S (2015) Structural insight into the mechanism of amyloid precursor protein recognition by β-secretase 1: a molecular dynamics study. Biophys Chem 202:1–12Google Scholar
  27. 27.
    Chakraborty S, Kumar S, Basu S (2011) Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study. Neurochem Int 58(8):914Google Scholar
  28. 28.
    CODESSA [computer program] (1995) Version 2.7.16. Comprehensive descriptor for structure and statistical analysis. Copyright center of heterocyclic chemistry, University of Florida and Institute of Chemical Physics, University of Tartu, Estonia and SemiChem IncGoogle Scholar
  29. 29.
    AMPAC 9.0, © (1994) Semichem, 7128 Summit, Shawnee, KS 66216Google Scholar
  30. 30.
    Chakraborty S, Basu S (2014) Insight into the anti-amyloidogenic activity of polyphenols and its application in virtual screening of phytochemical database. Med Chem Res.  https://doi.org/10.1007/s00044-014-1081-2
  31. 31.
    Chakraborty S, Basu S (2014) Mechanistic insight into the radical scavenging activity of polyphenols and its application in virtual screening of phytochemical library: an in silico approach. Eur Food Res Technol.  https://doi.org/10.1007/s00217-014-2285-x
  32. 32.
    Satyamitra M, Mantena S, Nair CKK, Chandna S, Dwarakanath BS, Devi PU (2014) The antioxidant flavonoids, orientin and vicenin enhance repair of radiation-induced damage. SAJ Pharm Pharmacol 1:1–9Google Scholar

Copyright information

© Springer Science+Business Media New York 2018

Authors and Affiliations

  1. 1.Department of MicrobiologyUniversity of CalcuttaKolkataIndia

Personalised recommendations